Clinical and economic outcomes after introduction of drug-eluting stents

American Journal of Managed Care

Volumn 16, Issue 8, 2010, Pages 580-587

  Rihal, Charanjit S ^a   Ryan, James L ^a   Singh, Mandeep ^a   Lennon, Ryan J ^a   Bresnahan, John F ^a   Liesinger, Juliette T ^a   Gersh, Bernard J ^a   Ting, Henry H ^a   Holmes Jr , David R ^a   Long, Kirsten Hall ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; ATHERECTOMY; BARE METAL STENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; COHORT STUDIES; CONFIDENCE INTERVALS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HEALTH CARE COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; LOGISTIC MODELS; MALE; MODELS, ECONOMIC; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77956121921     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Farb A, Boam AB. Stent thrombosis redux - the FDA perspective. N Engl J Med. 2007;356(10):984-987.
2. Morice MC, Serruys PW, Sousa JE, et al; RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773-1780.
3. Moses JW, Leon MB, Popma JJ, et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-1323.
4. Stone GW, Ellis SG, Cox DA, et al; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350(3):221-231.
5. Valgimigli M, Percoco G, Malagutti P, et al; STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005;293(17):2109-2117
6. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355(11):1105-1113.
7. Spaulding C, Henry P, Teiger E, et al; TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355(11):1093-1104.
8. Stone GW, Moses JW, Elllis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356(10):998-1008.
9. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L; SCAAR Study Group, Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009-1019.
10. Shuchman M. Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med. 2006;355(19):1949-1952.
11. Kong DF, Eisenstein EL, Sketch MH, et al. Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J. 2004;147(3):449-456.
12. Hodgson JM, Bottner RK, Klein LW, et al. Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. Catheter Cardiovasc Interv. 2004;62(1):1-17.
13. Gunn J, Morton AC, Wales C, Newman CM, Crossman DC, Cumberland DC, Drug eluting stents: maximising benefit and minimising cost. Heart. 2003;89(2);127-131.
14. Cohen DJ, Bakhai A, Shi C, et al; SIRUS Investigators. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial. Circulation. 2004;110(5);508-514.
15. Van Hout BA, Serruys PW, Lemos PA, et al. One year cost-effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart. 2005;9(4):507-512.
16. Bakhai A, Stone GW, Mahoney E, et al; TAXUS-IV Investigators. Cost effectiveness of paclitaxel-eluting stents for patients undergoing coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol. 2006;48(2):253-261.
17. Kaiser C, Brunner-La Rocca P, Buser PT, et al; BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET) (published correction appears in Lancet. 2005;366(9503):2086]. Lancet. 2005;366(9489):921-929.
18. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of baremetal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358(4):342-352.
19. Kindermann M, Adam O, Wemer N, Böhm M. Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol. 2007;96(11):767-786.
20. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357(14):1393-1402.
21. Hannan EL, Racz M, Holmes DR, et al. Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents. Circulation. 2008;117(16):2071-2078.
22. Groeneveld PW, Matta MA, Greenhut AP, Yang F. Drug-eluting compared with bare-metal coronary stents among elderly patients. J Am Coll Cardiol. 2008;51(21):2017-2024.
23. Groeneveld PW, Matta MA, Greenhut AP, Yang F. The costs of drug-eluting coronary stents among Medicare beneficiaries. Am Heart J. 2008;155(6):1097-1105.
24. Malenka DJ, Kaplan AV, Lucas FL, Sharp SM, Skinner JS. Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA. 2008;299(24):2868-2876.
25. Hasdai D, Garratt KN, Grill DE, Lerman A, Holmes DR Jr. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med. 1997;336(11):755-761.
26. Holmes DR Jr, Vlietstra RE. Percutaneous transluminal coronary angioplasty: current status and future trends. Mayo Clin Proc. 1986;61(11):865-876.
27. Rihal CS, Kamath CC, Holmes DR Jr, et al. Economic and clinical outcomes of a physician-led continuous quality improvement intervention in the delivery of percutaneous coronary intervention. Am J Manag Care. 2006;12(8):445-452.
28. Singh M, Rihal CS, Lennon RJ, Garratt KN, Holmes DR Jr. Comparison of Mayo Clinic risk score and American College of Cardiology/American Heart Association lesion classification in the prediction of adverse cardiovascular outcome following percutaneous coronary interventions. J Am Coll Cardiol. 2004;44(2):357-361.
29. Healthcare Cost and Utilization Project (HCUP). Overview of the Nationwide Inpatient Sample (NIS). 2004. http://www.hcup-us.ahrq.gov/ nisoverview.jsp.
30. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 pt 2):757-763.
31. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
32. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Boca Raton, FL: Chapman & Hall/CRC; 1998.
33. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy. 1998;3(4):233-245.
34. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004;9(4);197-204.
35. Manning WG, Mullahy J, Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461-494.
36. Afifi AA, Kotlerman JB, Ettner SL, Cowan M. Methods for improving regression analysis for skewed continuous or count responses. Annu Rev Public Health. 2007;28:95-111.
37. Yang EH, Gumina RJ, Lennon RJ, Holmes DR Jr, Rihal CS, Singh M. Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol. 2005;46(11):2004-2009.
38. Singh M, Rihal CS, Gersh BJ, et al. Twenty-five year trends in in-hospital and long-term outcome after percutaneous coronary intervention: a single-institution experience. Circulation. 2007;115(22):2835-2841.